Navigation Links
Actinobac Biomed Selected to Present at Cavendish Global Health Impact Forum

NEW BRUNSWICK, N.J., April 13, 2015 /PRNewswire-USNewswire/ -- Actinobac Biomed, Inc., a start-up biopharmaceutical company developing drugs to treat immune-related cancers and diseases, has been selected to present their findings and therapeutic technology at the Cavendish Global Health Impact Forum on May 10th to May 14th in La Jolla, California. 

The Forum's theme, a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World,' aims to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving and philanthropy programs within health and the life sciences. Presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment will be featured.  

"We are honored to be selected to present at this unique event and look forward to discussing our innovative approach to treat diseases that affect white blood cells which afflict millions of people around the world today," said Dr. Benjamin Belinka, president and CEO of Actinobac. "We welcome the chance to interact with many of the world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations which they are passionate about with other family offices from around the world.

"With the help of our expert advisors, we conducted a global search of research institutions and private-sector companies to identify organizations that meet the required standard of excellence," explained Michael Moffat, Cavendish co-founder and chief executive officer.  "The quality and originality of Actinobac Biomed's research and scientific insights in the development of therapy that naturally targets and eliminates diseased white blood cells positions them to make a major contribution to the treatment of many life-threatening and debilitating diseases such as leukemia, lymphoma and autoimmune diseases."

About Actinobac Biomed, Inc.
Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases and HIV. Drug candidates are based on Leukothera®, a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Leukothera® functions by depleting and preventing migration of the activated immune cells involved in diseases of white blood cells. The cellular receptor for Leukothera™ is lymphocyte function associated antigen-1 (LFA-1). Since LFA-1 is expressed only on WBCs, other cells and tissues of the body are not affected.

More information is available at or by contacting Benjamin Belinka at

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

For more information visit the website at or contact Alex Charlton, president, at or 917-576-1435.


SOURCE Actinobac Biomed, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
4. BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend
5. BioMed Realty To Lease 204,900 Square Feet To Life Technologies At The Science Center at Oyster Point In South San Francisco
6. Suspect Detection Systems Receives Funding From Israel-Publicly Traded Biomedix Ltd.
7. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
8. Start a Healthy Tradition this Earth Day: Tips from Topical BioMedics on How to Detox the Family Medicine Cabinet
9. Cellular Biomedicine Group Provides Update and 2013 Milestones
10. Premier Biomedical CEO Interviewed by The Wall Street Transcript
11. Oxford BioMedica Announces Update from ARVO 2013
Post Your Comments:
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien ... announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical ... development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... of 40% in 2020, despite many obstacles created as a result of COVID-19. ... revenue for its partnered medical practices and medical manufacturers by expanding access to ...
(Date:6/28/2020)... ... 25, 2020 , ... The Indoor Lab, a leading provider of sensor solutions ... all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology ... business will provide a health performance index system that scores all aspects of compliance ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... ... association representing security solutions providers, today announced its strong opposition to the recently ... bill would impose a blanket ban on most federal use of nearly all ...
Breaking Biology Technology:
(Date:7/10/2020)... ... 2020 , ... Today CJ BIO announced the first in a series of ... taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a ... July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... solutions for glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments ... Senior Fellows are charged with supporting the organization’s initiatives and overall vision. , ...
(Date:6/23/2020)... KEYNES, England (PRWEB) , ... June 23, 2020 ... ... in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer ... response project to support testing operations in the fight against the COVID-19 pandemic ...
Breaking Biology News(10 mins):